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A B S T R A C T
Leucine-rich repeat kinase 2 (LRRK2) is genetically implicated in both familial and sporadic Parkinson's disease
(PD). Moreover, LRRK2 has emerged as a compelling therapeutic target for the treatment of PD. Consequently,
there is much interest in understanding LRRK2 and its role in PD pathogenesis. LRRK2 is constitutively phos-
phorylated on two serines, S910 and S935, that are required for interaction of LRRK2 with members of the 14-3-
3 family of scaﬀolding proteins. Pathogenic LRRK2 missense mutations impair the phosphorylation of LRRK2 at
these sites, but whether this contributes to PD pathology is unclear. To better understand how loss of LRRK2
phosphorylation relates to PD pathology, we have studied double knockin mice in which Lrrk2's serine 910 and
935 have both been mutated to alanine and can therefore no longer be phosphorylated. Nigrostriatal PD pa-
thology was assessed in adult mice, aged mice, and mice inoculated with α-synuclein ﬁbrils. Under all paradigms
there was evidence of early PD pathology in the striatum of the knockin mice, namely alterations in dopamine
regulating proteins and accumulation of α-synuclein. Striatal pathology was accompanied by a signiﬁcant de-
crease in the number of astrocytes in the knockin mice. Despite striatal pathology, there was no degeneration of
dopamine neurons in the substantia nigra and no evidence of a PD motor phenotype in the knockin mice. Our
results suggest that modulation of LRRK2 serine 910 and 935 phosphorylation sites may have implications for
dopamine turnover and astrocyte function, but loss of phosphorylation at these residues is not suﬃcient to
induce PD neurodegeneration.
1. Introduction
Genetic and clinical evidence suggest a pathogenic role for leucine-
rich repeat kinase 2 (LRRK2) in both sporadic and familial Parkinson's
disease (PD) (Healy et al., 2008; Nalls et al., 2014; Paisan-Ruiz et al.,
2004; Zimprich et al., 2004). Exactly how LRRK2 function or dys-
function leads to PD pathogenesis however, remains unclear. LRRK2 is
a large 280 kDa protein with both kinase and GTPase activities, as well
as leucine-rich repeat, armadillo repeat and WD40 repeat protein-pro-
tein interaction domains. Among the ﬁrst LRRK2 interacting proteins
identiﬁed were members of the 14-3-3 family of regulatory proteins (Li
et al., 2011; Nichols et al., 2010). Six out of the seven 14-3-3 isoforms
interact with LRRK2 in a manner dependent on the phosphorylation of
LRRK2 at serine (S) 910 and S935, two residues found just prior to the
proteins leucine-rich repeat domain (Nichols et al., 2010; Stevers et al.,
2017). In overexpressing cell culture models, ablation of S910 and S935
phosphorylation via mutation of these residues to alanine, results in the
loss of 14-3-3 binding and the accumulation of LRRK2 in the cytoplasm
(Nichols et al., 2010). This suggests a role for S910 and S935 phos-
phorylation in the regulation of LRRK2's subcellular localization.
There are at least six pathogenic missense mutations in LRRK2
(R1441C, R1441G, R1441H, Y1699C, G2019S and I2020T), that all
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occur in domains important for regulating LRRK2 catalytic activities
(Cookson, 2010). Strikingly, all of these mutations (except for G2019S)
result in a loss of LRRK2 S910 and S935 phosphorylation in both cell
culture models and knockin mice (Nichols et al., 2010). Overexpressing
these loss of phosphorylation pathogenic LRRK2 variants in cell culture
results in the accumulation of LRRK2 in cytoplasmic pools (Nichols
et al., 2010). More recently, reduced LRRK2 S910 and S935 phos-
phorylation has also been observed in post mortem brain tissue from
patients with idiopathic Parkinson's disease (Dzamko et al., 2017). In
this study, a signiﬁcant reduction in both S910 and S935 phosphor-
ylation was observed in pathologically aﬀected brain regions. That loss
of LRRK2 phosphorylation at S910 and S935 occurs in familial and
sporadic PD may suggest a potential pathogenic role for these residues
in PD.
Somewhat counterintuitively therefore, is the prominent role for the
S910 and S935 phosphorylation sites as pharmacodynamic biomarkers
for LRRK2 kinase inhibitors. In this regard, it has been established in
cells, mice, primates and humans, that LRRK2 kinase inhibitor treat-
ment results in a dose-dependent decrease in LRRK2 S910 and S935
phosphorylation (Deng et al., 2011; Dzamko et al., 2010; Fuji et al.,
2015; Perera et al., 2016). The S910 and S935 residues are not direct
LRRK2 autophosphorylation sites, but their phosphorylation is in-
directly regulated in a LRRK2 kinase activity-dependent manner, po-
tentially via other upstream kinases such as inhibitor of kappa B kinase
(IKK) and casein kinase (CK) family members (Chia et al., 2014;
Dzamko et al., 2012) as well as upstream phosphatases (Lobbestael
et al., 2013). Similar to the above described eﬀects following mutation
of S910 and S935 to alanine, LRRK2 inhibitor treatment of over-
expressing cell systems also results in the accumulation of LRRK2 in the
cytoplasm (Deng et al., 2011; Nichols et al., 2010), as well as increased
ubiquitination of LRRK2 leading to its proteosomal degradation
(Lobbestael et al., 2016; Zhao et al., 2015). However, accumulating
evidence from pre-clinical cell and animal studies suggest that LRRK2
kinase inhibitors may actually have protective eﬀects in some PD
models (Atashrazm and Dzamko, 2016; West, 2015). Furthermore, it is
established that the six conﬁrmed LRRK2 pathogenic mutations all in-
crease the kinase activity of LRRK2 (Sheng et al., 2012; Steger et al.,
2016), and thus there is substantial interest in developing LRRK2 in-
hibitors as potential PD therapeutics (Chan and Tan, 2017; West, 2017).
Thus, both pathological mutations and potential therapeutics alter
LRRK2 S910 and S935 phosphorylation, suggesting a better under-
standing of the physiological roles of these phosphorylation sites is
warranted.
To gain further insight into LRRK2 phosphorylation we have studied
adult, aged and α-synuclein ﬁbril-inoculated Lrrk2 S910A/S935A
double knockin mice, to determine how the loss of Lrrk2 phosphor-
ylation impacts on PD-like nigrostriatal pathology under these diﬀerent
conditions.
2. Material and methods
2.1. Mice
Lrrk2 S910A/S935A double knockin mice backcrossed onto a
C57BL6 background were provided by Dario Alessi, University of
Dundee. The mice were re-derived into our animal facility and het-
erozygous breeding established to provide wild type and double
S910A/S935A knockin (KI) littermate mice for study. All animal work
was approved by the University of NSW animal ethics committee (ap-
proval numbers 15-28B and 16-24A) and experiments performed in
accordance with the Australian code for the care and use of animals for
scientiﬁc purposes. Both male and female mice were used. Mice were
maintained on a 12 h light-dark cycle with food and water ad libitum.
Diﬀerent cohorts of mice were studied at 3months old, 18 months old
and following α-synuclein inoculation as outlined in Supplementary
Fig. 1. Mice were maintained on a 12 h light-dark cycle with food and
water ad libitum. The 18-month-old mice were raised and perfused at
the University of Dundee with ﬁxed brain tissue shipped for analysis.
2.2. Genotyping
Genomic DNA was puriﬁed from mouse tail tissue using digestion
buﬀer (0.05mM EDTA; pH 8.0, 200mM NaCl, 100mM Tris, 0.2% (w/v)
SDS) and 0.1 mg/ml of proteinase K at 55 °C overnight. DNA was then
precipitated in 100% ethanol and washed with 70% ethanol. Genomic
DNA was genotyped using forward (GTGCTTGAAGTTTGATCATAA
TGC) and reverse (GCATATAGCATGTAGTGTCATCTCC) primers
(Sigma) and GoTaq® Master Mix (Promega). SYBR Safe DNA Gel Stain
(Invitrogen) was used for PCR product visualization using a Chemidoc
MP Imaging system (Biorad). LRRK2 wild-type was identiﬁed by a
single band at 326 bp, and the homozygote LRRK2 knock-in genotype
by a single band at 401 bp (Supplementary Fig. 2).
2.3. α-synuclein ﬁbril preparation
Recombinant human monomeric α-synuclein for generating pre-
formed ﬁbrils was obtained from Proteos. For generating ﬁbrils for
inoculation we followed the supplied protocol, which has recently been
published (Polinski et al., 2018). Brieﬂy, upon thawing, the monomeric
α-synuclein protein was diluted to 5mg/ml in sterile Dulbecco's phos-
phate buﬀered saline (DPBS) and continuously shaken at 1000 rpm on
an orbital shaker placed in a 37 °C incubator for 7 days. After this time,
the presence of ﬁbrils was conﬁrmed by Thioﬂavin T assay. For this
assay, Thioﬂavin T (Sigma) was diluted to 25 μM in DPBS. 95 μl of di-
luted Thioﬂavin T was then mixed with 2.5 μl of ﬁbrillar, or the original
stock monomeric α-synuclein as a control, in a black 96 well microplate
(Greiner) and incubated at room temperature for 5min. After incuba-
tion, the plate was read with excitation and emission settings of 450 nm
and 480 nm respectively, using a Polarstar plate reader (BMG Labteck).
25 μl aliquots of ﬁbrillar α-synuclein were then stored at −80 °C and
the same preparation was used for all inoculations. Daily before sur-
gery, the ﬁbrillar α-synuclein was diluted to 1mg/ml in DBPS and so-
nicated (Branson Sonifer 250 with microtip, output control= 1, Duty
cycle= 10%, Time=30 s) to generate smaller α-synuclein pre-formed
ﬁbrils (PFF) for injection.
2.4. Transmission electron microscopy
For transmission electron microscopy, 3 μl of 0.1 mg/ml sonicated
or un-sonicated PFF samples were applied to glow-discharged 200
mesh, carbon-only, copper grids (Electron Microscopy Sciences) and
negatively stained with 2% uranyl acetate (Polysciences). The grids
were imaged in a Philips CM120 electron microscope operated at
200 kV with nominal magniﬁcation at 66,000× and a defocus range of
−1.0 μm to −1.27 μm. Images were collected on a Gatan Ultrascan
4000 CCD camera.
2.5. Stereotactic injection
Male and female mice at 3months of age were anesthetized by in-
traperitoneal injection of ketamine hydrochloride (75–100mg/kg of
body weight) and xylazine (10–20mg/kg body weight), and inoculated
with 2 μl of PFF (1mg/ml) or sterile phosphate buﬀered saline (PBS) by
stereotactic injection. Material was injected into the right hemisphere,
targeting the dorsal striatum (located +0.2mm from the Bregma,
+2.25mm from midline and a depth of +2.6mm from the dura) and
injected by a Hamilton syringe at a rate of 0.1 μl per min. The needle
was left in situ for at least 10min to allow injected material to spread
into the surrounding parenchymal area. Once fully recovered from
anaesthesia, the mice were monitored at least once daily for any sign of
post-operative complications for 7 days.
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2.6. Behavioural testing
To assess the onset and progression of Parkinson's-disease-related
symptoms, behavioural tests were performed at baseline, after habi-
tuation at the animal facility for 1 week, followed by assessment at 3
and 6months post stereotactic injection, when the mice were 6 and
9months old respectively. Tests were performed between 8:00–12:00 in
the light-on cycle for two consecutive days, with 30min break in be-
tween each test. Mice were acclimatized to the testing rooms in their
home cage for 1 h prior to tests. All testing apparatus and equipment
were cleaned with 70% ethanol in between each mouse. Equal numbers
of male and female mice were used. General activity, locomotion and
anxiety were assessed by open-ﬁeld (Brooks and Dunnett, 2009). The
open-ﬁeld apparatus (MED Associates Inc.) was an evenly illuminated
square arena (43.2 cm×43.2 cm) with transparent Plexiglas walls and
white ﬂoor. Mice were individually placed in the corner of the arena.
The horizontal activity of each mouse was measured by infra-red beams
for 60min, the ﬁrst 30min of which is for habituation activity and the
following 30min for evaluation of locomotor activity. Motor co-
ordination and balance were assessed by rota-rod testing (Brooks and
Dunnett, 2009). The mice were placed on the rota-rod apparatus (Co-
lumbus Instruments) at an initial speed of 4 rpm. The mice were ex-
posed to 4 trials. Over 300 s the speed gradually increased from 4 to
40 rpm for the ﬁrst 2 trials and then 4 to 50 rpm for the subsequent 2
trials, with all trials being performed at 10min intervals. Within this
time, the latency of the mice to fall oﬀ the rota-rod was recorded. At
baseline, the mice were given a training session (4 trials of 4–40 rpm)
for acclimatization to the apparatus prior to testing. The mean latency
to fall for each speed was used for analysis.
2.7. Tissue preparation
For generating tissues for immunoblotting, mice were anesthetized
with isoﬂurane followed by cervical dislocation. Tissues were rapidly
excised and snap-frozen in liquid nitrogen for later analysis. For gen-
erating tissues for fractionation, 200mg of fresh mouse tissue was
homogenized using a polytron handheld homogenizer. Cytoplasmic,
membrane, nuclear, chromatin bound and cytoskeletal fractions were
then sequentially extracted using a detergent-based subcellular protein
fraction kit (#87790 ThermoFisher) exactly as per manufacturers' in-
structions. Fractions were snap frozen and stored at −80 °C until ana-
lysis by immunoblot. For generating tissues for immunohistochemistry,
mice were administered a lethal intraperitoneal dose of sodium pen-
tobarbital (80–100mg/kg body weight). Transcardial perfusion was
then performed with PBS, followed by cold 4% paraformaldehyde
(PFA) ﬁxative diluted in PBS (pH 7.4). The brain was removed and
placed in 4% PFA for post-ﬁxation overnight at 4 °C. Tail tips were
collected from all mice following perfusion and genotypes reconﬁrmed.
2.8. Immunoblotting
Snap-frozen tissues from mouse brain, lung, kidney and spleen were
homogenized in buﬀer consisting of 50mM Tris.HCL pH 7.5, 1 mM
EGTA, 1mM EDTA, 1mM sodium orthovanadate, 50 mM sodium
ﬂuoride, 5 mM sodium pyrophosphate, 0.27M sucrose, 1 mM benza-
midine, 1 mM PMSF and 1% Triton X-100. Protein concentration was
measured using a bicinchoninic acid assay (Pierce BCA Protein Assay
Kit, ThermoFisher) and made up to 2mg/ml in 1 x lithium dodecyl
sulfate sample buﬀer (ThermoFisher) containing 20 μl/ml of 2-mer-
captoethanol. Protein lysates were separated by reducing SDS-PAGE.
After wet transfer to nitrocellulose membranes, non-speciﬁc binding
was blocked with 5% skim milk dissolved in TBS buﬀer containing 0.1%
Tween-20 (Sigma) and membranes were then incubated in primary
antibodies overnight at 4 °C. After incubation with either horseradish
peroxidase (HRP)-conjugated secondary antibodies or Alexa Fluor (AF)-
conjugated secondary antibodies, protein detection was visualized
using enhanced chemiluminescence reagent (GE Healthcare) and a
Chemidoc MP Imaging system (Biorad). Details of antibodies for wes-
tern blot are provided in supplementary table 1. The intensity level of
protein of interest was quantiﬁed using ImageLab software (Biorad) and
expressed as arbitrary units standardized to β-actin protein levels.
Protein levels were then expressed as a percentage relative to the
control group, which was set at 100%. Immunoblots are shown in the
relevant ﬁgures. Students t-test was used to compare between the two
groups.
2.9. Immunohistochemistry
Following post-ﬁxation, tissues were cryo-protected in 5ml 30%
sucrose diluted in PBS at 4 °C for approximately 24 h (time to sink to the
bottom of the container). Each cryo-protected brain was then frozen
onto a chuck for serial coronal sectioning at 40 μm using a Leica 1850
cryostat (Leica Microsystems). Sections containing the amygdala and all
basal ganglia structures were collected from Bregma 1.18mm to
Bregma −4.04mm with every 1/6 section collected into a series of
separate containers of PBS to create 6 series of sections. All midbrain
sections were collected and every 1/6 section put into separate con-
tainers of PBS to create 6 series of midbrain sections. The Ser129
phosphorylated α-synuclein antibody (clone 81A) was a kind gift from
Virginia Lee, University of Pennsylvania and was used as previously
described (Luk et al., 2012). Details of the other antibodies used for
immunoﬂuorescence labelling are given in supplementary table 2. Im-
munostaining was carried out simultaneously for each marker in the
same region from the same group. Sections were initially incubated in
10mM sodium citrate buﬀer (pH 6.0) for 1 h at 85 °C for antigen re-
trieval. All sections were then washed in PBS and non-speciﬁc sites
blocked by serum incubation (either 10% goat or 10% donkey serum
(both Sigma) depending on secondary antibody used) in 0.3% Triton-X
100 in PBS for 1 h at room temperature. Incubation with primary an-
tibodies was for 2 days at 4 °C followed by PBS washes. Alexa Fluor-
conjugated secondary antibodies were used for 2 h at room tempera-
ture. Sections were washed, counterstained with DAPI, mounted and
coverslipped with anti-fade mounting medium (Dako). Speciﬁcity of the
immunoﬂuorescence reaction was validated by omitting the primary
antibody and observing no ﬂuorescence staining.
2.10. Histochemical analyses
Mouse brain structures were deﬁned according to the Mouse Brain
in Stereotaxic Coordinates (Paxinos and Franklin, 2012). Regions of
interest identiﬁed for analyses were the TH or DAT immunoreactive
substantia nigra pars compacta (SNpc) assessed in a 1/6 series of 40 μm
thick coronal sections (5–7 sections per mouse), the dorsolateral
striatum assessed in a 1/6 series of 40 μm thick coronal sections (5–6
sections per mouse) and the cortical nucleus within the corticomedial
complex of the amygdala in a 1/6 series of 40 μm thick coronal sections
(5–6 sections per mouse). Informative confocal images for each im-
munoﬂuorescence marker from each region from each group of mice
were captured using the same confocal microscope - either a Nikon C2
Basic or Eclipse 90i with NIS-Elements advanced research imaging
software or a Zeiss 710 LSM confocal microscope equipped with Zen
2010 software. For each region, the same camera settings were used,
including laser intensity, detector sensitivity, averaging times, pixel
dwell, etc. For three-dimensional image stacks, the NIS-Elements soft-
ware automatically set the focal distance. All informative images pre-
sented in the ﬁgures were processed by Adobe Photoshop (Adobe Sys-
tems Inc.) under the same condition (brightness and contrast setting).
Prism (Graphpad software) was used for statistical analyses of the
number of identiﬁed cells with and without α-synuclein im-
munopositive inclusions, and the intensity of ﬂuorescence labelling, as
described below. A p value of 0.05 was considered signiﬁcant. Student's
t-test was used to compare between two groups. Two-way ANOVA with
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Tukey's multiple comparison test was used to compare between the WT
and KI mice that had been inoculated with PBS or PFFs.
2.10.1. Quantitation of the number of TH-immunoreactive neurons in the
SNpc
All SNpc containing sections from the 3-month-old and the PBS or
PFF inoculated mice were analysed stereologically using an Axio
Imager M2 ﬂuorescent microscope (Zeiss) and Stereo Investigator 10.0
software (MBF Bioscience). The SNpc region of interest was outlined for
sampling, and live focus and an optical fractionator stereological probe
(box size= 30×30×30 μm3 sampling 2 cells on average per box; grid
sampling array 137 μm×101 μm with 12.8 ± 0.5 boxes sampled)
used to obtain an unbiased stereological sample within this region. Only
those neurons whose nuclei fell entirely inside the probes frame or
touching the green inclusion borders of the probe were counted.
Repeated measures in 25% of sections by the same assessor varied
by<6%. For the analysis of brain tissue from 18-month-old mice, a
stereological fractionator technique was used with images of the entire
SNpc in spaced sections captured at 10× magniﬁcation and the number
of all TH immunoﬂuorescent neurons determined within each section
using the manual count tool in Adobe Photoshop. For each aged mouse,
the total number of TH immunoreactive neurons was estimated by
multiplying the sum of the number counted per section ×6. Repeated
measures in 25% of sections by the same assessor varied by< 8%. For
all studies, TH neuron counts in KI mice were expressed as a percent of
wild type mice, which was set at 100%.
2.10.2. Assessment of the cellular intensity of dopaminergic markers
For the SNpc, DAPI labelled (29 ± 1 average number per mouse) or
TH immunoreactive (28 ± 1 average number per mouse) neurons were
identiﬁed in 40× confocal images, and the DAT and Vmat2 levels de-
termined within each neuron following background correction to the
cerebral peduncle using Image J software. Repeated measures in 20% of
sections by the same assessor varied by<4%. For the 3-month-old and
the PBS or PFF inoculated WT and KI mice, 10 randomly selected non-
overlapping 15×15 μm2 ﬁelds from the dorsolateral striatum at 20×
or ~0.17 μm/pixel magniﬁcation was used for TH, DAT and Vmat2
immunoﬂuorescence. The relative intensity of immunoﬂuorescent sy-
napses was determined following background correction to the corpus
callosum using Image J software. Repeated measures in 20% of sections
by the same assessor varied by<6%. For 18-month-old KI mice, low
magniﬁcation images for TH sampling the whole dorsolateral striatum
(2.5× or ~4.5 μm/pixel magniﬁcation on an Axio Imager M2 ﬂuor-
escent microscope with 160×160 μm2 area sampled per mouse), and
higher magniﬁcation confocal images for DAT (40× or ~0.3 μm/pixel)
and Vmat2 (100× or ~0.12 μm/pixel) in 10 randomly selected non-
overlapping 15× 15 μm2 ﬁelds from the dorsolateral striatum were
assessed. The intensity levels of these markers were expressed as the
percentage of the average of the WT group, which was set at 100%.
2.10.3. Assessment of α-synuclein immunopositive cytoplasmic and synaptic
staining
In the SNpc, α-synuclein was co-stained with TH to examine the
proportion of α-synuclein positive cells co-localizing with TH-im-
munoreactive neurons (21 ± 1 average number sampled per mouse)
using Image J software. First, cytoplasmic α-synuclein intensity was
identiﬁed as that being higher than the average intensity of the sec-
tional background (n=10 background loci/section) corrected to the
background levels in the cerebral peduncle in 40× or ~0.15 μm/pixel
magniﬁed confocal images. The Image J JACoP plugin was used to
determine the proportion of co-localization. Repeated measures in 20%
of sections by the same assessor varied by<4%. For the intensity of the
synaptic α-synuclein terminals in the dorsolateral striatum and amyg-
dala, the measured intensity levels were expressed as the percentage of
the average of the WT group, which was set at 100%. For the 3-month-
old and the PBS or PFF inoculated WT and KI mice, 10 randomly
selected non-overlapping 15×15 μm2 ﬁelds from the dorsolateral
striatum at 20× or ~0.17 μm/pixel magniﬁcation was used for α-sy-
nuclein immunoﬂuorescence. The relative intensity of α-synuclein sy-
naptic immunostaining was determined following background correc-
tion to the corpus callosum using Image J software. Repeated measures
in 20% of sections by the same assessor varied by< 5%. In the amyg-
dala, the intensity was assessed in 10 randomly selected non-over-
lapping 10×10 μm2 ﬁelds in 40× or ~0.3 μm/pixel magniﬁed con-
focal images. Repeated measures in 15% of sections by the same
assessor varied by<5%. For the dorsolateral striatum in the 18-month-
old mice, low magniﬁcation images for α-synuclein sampling the whole
dorsolateral striatum (2.5× or ~4.5 μm/pixel magniﬁcation on an Axio
Imager M2 ﬂuorescent microscope with 160× 160 μm2 area sampled
per mouse) were assessed.
2.10.4. Quantitation of the number of glial cells
DAPI labelled Iba1 immunoreactive microglia were assessed in the
SN by sampling two-four captured images/SN section at 40× or
~0.15 μm/pixel magniﬁcation (6 ± 1 average microglia per sampled
image, 18 ± 3 images per mouse SN). The sampled SN image con-
tained both SNpc and SNpr, that were diﬀerentiated for counting mi-
croglia by co-labelling with. Microglia were quantiﬁed in the dorso-
lateral striatum by sampling the entire region at 20× or ~0.17 μm/
pixel magniﬁcation (9 ± 1 average microglia per sampled image, 1
image/section, 5–6 images per mouse dorsolateral striatum). Repeated
measures in 20% of sections by the same assessor varied by< 4%. DAPI
labelled Gfap immunoreactive astrocytes were assessed in the dorso-
lateral striatum by sampling the entire region at 20× or ~0.17 μm/
pixel magniﬁcation (4 ± 1 average astrocytes per sampled image, 1
image/section, 5–6 images per mouse dorsolateral striatum), and in the
amygdala by sampling the entire cortical nucleus at 40× or ~0.15 μm/
pixel magniﬁcation (4 ± 1 average astrocytes per sampled image, 1
image/section, 5–6 images per mouse cortical nucleus in the amyg-
dala). Repeated measures in 15% of sections by the same assessor
varied by<3%. Glia adjacent to or within the corpus callosum and
blood vessels were excluded. The number of immunoﬂuorescent cells
was determined within standardized sampled regions using the manual
count tool in Image J software and the average number calculated per
standardized image view. The number of glia cells was expressed as the
percentage of the average of the WT group, which was set at 100%.
3. Results
3.1. Eﬀect of S910A/S935A KI on Lrrk2 protein, activity and subcellular
localization
We ﬁrst collected tissues from 3-month-old untreated mice to assess
the eﬀect that mutating S910A and S935A would have on the expres-
sion of endogenous Lrrk2, as well as phosphorylation of its downstream
substrate, Rab10. Correct genotyping of the mice was conﬁrmed by
complete loss of the S935 phosphorylation site in the KI mice in all
tissues examined (Fig. 1A–D). In brain, lung and spleen tissue, levels of
total Lrrk2 and phosphorylation of Rab10 T73 were similar between the
wild type and KI mice, however in kidney, both total levels of Lrrk2 and
Rab10 T73 phosphorylation were reduced in the KI mice (Fig. 1A–D).
As knockout of Lrrk2 in kidney has previously been associated with
morphological changes (Tong et al., 2010), we examined kidney ap-
pearance and weight in the KI mice, but found no diﬀerence compared
to wild type (Supplementary. Fig. 3). We next aimed to determine if KI
mice had an altered subcellular localization of Lrrk2. Subcellular frac-
tionation experiments using brain tissue showed similar levels of Lrrk2
in the nuclear, chromatin bound and cytoskeletal fractions, whereas
Lrrk2 levels appeared lower in the cytoplasmic and membrane bound
fractions of the KI mice (Fig. 1E). To better quantify the fractionation
results, we re-blotted both the cytoplasmic and the membrane-bound
fractions with wild type and KI mice side-by-side. This showed a similar
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level of Lrrk2 in the cytoplasmic fraction (Fig. 1F), but a signiﬁcantly
reduced level of Lrrk2 in the membrane-bound fraction (Fig. 1G) of the
KI mice.
3.2. Reduced dopamine regulating proteins with increased α-synuclein in
adult KI mice striatum
We next went on to further characterize brain tissue from untreated
wild type and KI mice of 3months of age. Due to its relevance to PD, we
focused on α-synuclein and proteins of the nigrostriatal dopamine
Fig. 1. Eﬀect of LRRK2 S910A/S935A mutation on LRRK2 protein, activity and subcellular localization. Lrrk2 phosphorylation at serine 935, total Lrrk2, phos-
phorylated T73 Rab10 and total Rab10 were assessed by immunoblot in the brain (A), kidney (B), lung (C) and spleen (D) from the adult wild type and Lrrk2 S910A/
S935A KI mice at 3months of age. β-actin was used as a loading control. (E) Following fractionation, Lrrk22 levels were measured by immunoblot in the cytoplasmic
extract (CE), membrane extract (ME), nuclear extract (NE), chromatin bound (CB) and cytoskeletal (CS) fractions using brain tissue from the adult wild type and KI
mice at 3 months of age. Representative immunoblots are shown from n=4 mice. Brain protein levels of Lrrk2 were expressed in the cytoplasm (F) and membrane
(G) fractions as the percent of the wild type group, which was set at 100%. Quantiﬁed immunoblot data are presented as mean ± SEM. Student's t-test was used to
compare the groups. *Indicates p < .01 compared to wild type.
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pathway. In the dorsolateral striatum of the KI mice, we found a sig-
niﬁcant decrease in staining intensity of the dopamine regulating pro-
teins TH, DAT and Vmat2 (8%, 8% and 16% respectively and all
p < .01) as compared to wild type (Fig. 2A–C). This was accompanied
by a signiﬁcant increase (73%, p < .001) in the intensity of α-synu-
clein staining (Fig. 2D). The number of Gfap positive astrocytes in the
striatum of the KI mice trended lower, but were not signiﬁcantly dif-
ferent (Fig. 2E), whereas the number of Iba1 positive microglia were
the same in both genotypes (Fig. 2F). In contrast to the striatum, in the
TH positive SNpc neurons, we found only a small decrease in Vmat2
(9%, p < .01, Fig. 2G), whilst the intensity of DAT (Supplementary
Fig. 4A) and α-synuclein were unchanged (Supplementary Fig. 4B).
Stereological counting revealed no diﬀerence between the two groups
in the number of TH immunopositive SNpc neurons (Fig. 2H), whilst
the number of Iba1 positive microglia in the entire SN were also similar
between the two groups (Supplementary Fig. 4C).
3.3. Nigrostriatal pathology with reduced astrocytes in aged S910A/S935A
KI mice striatum
To determine whether changes in the nigrostriatal dopamine
pathway were altered with age, we next studied brain tissue from wild
type and KI mice at an age of 18months. In the dorsolateral striatum of
the aged KI mice, we found a signiﬁcant decrease in the intensity of TH
immunoreactivity (9%, p < .001, Fig. 3A). Intensity levels of DAT
were similar between the two genotypes (Fig. 3B), however, Vmat2
immunoﬂuorescence intensity was increased in KI mice (47%,
p < .001, Fig. 3C). Although the intensity of α-synuclein in the dor-
solateral striatum was similar between wild type and KI groups
(Fig. 3D), a small number of abnormal α-synuclein immunopositive
inclusions were observed in the KI mice but not in the wild type mice
(Supplementary Fig. 5A). These inclusions were located in small, non-
TH immunoreactive cells as determined by their association with DAPI-
positive nuclei. Intriguingly, there was a signiﬁcant decrease in the
number of Gfap positive astrocytes in the dorsolateral striatum of the KI
mice (54%, p < .001, Fig. 3E), whereas the number of Iba1 positive
microglia remained unchanged (Supplementary Fig. 5B). In the SNpc,
there was no diﬀerence either in the number of TH positive neurons
(Fig. 3F), or the intensity levels of neuronal DAT (Supplementary
Fig. 5C) or Vmat2 (Supplementary Fig. 5D) between the two genotypes.
In contrast, there was a non-signiﬁcant trend for an increased propor-
tion of TH positive SNpc neurons to contain α-synuclein accumulations
in the KI mice (of ~50%, p= .06, Fig. 3G). This change was associated
with a 20% increase in the number of Iba1 positive microglia in the SN,
in particular in the substantia nigra pars reticulata, of the KI group
(Fig. 3H).
3.4. PFF inoculation and behavioural testing in S910A/S935A KI mice
We next aimed to determine if loss of Lrrk2 S910 and S935 phos-
phorylation could potentiate α-synuclein pathology induced by intra-
striatal injection of PFFs. Prior to surgery, rota-rod and open ﬁeld tests
Fig. 2. Reduced dopamine regulating proteins with increased α-synuclein in the striatum of adult LRRK2 S910A/S935A KI mice. The intensity of TH (green) (A), DAT
(green) (B), Vmat2 (red) (C) and α-synuclein (green) (D) was measured in the dorsolateral striatum of adult WT (n= 8) and KI (n=8) mice at 3months of age. (E, F)
The number of Gfap (red) (E) and Iba1 (red) (F) positive glia cells were also counted in the dorsolateral striatum. The intensity of Vmat2 (red) (G) and the number of
TH (green) positive neurons (H) were measured in the substantia nigra from the same animals. The intensity levels of the immunoﬂuorescent markers and the number
of glia cells and TH positive neurons in the substantia nigra were expressed as the per cent of the wild type group, which was set at 100%. The blue staining is DAPI.
Data are presented as mean ± SEM. All images are representative of at least n= 6 per mouse. Student's t-test was used to compare the groups. ** indicates p < .01,
*** indicates p < .001 and **** indicates p < .0001 compared to the wild type mice. (For interpretation of the references to colour in this ﬁgure legend, the reader
is referred to the web version of this article.)
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were conducted using wild type and KI mice at 3months of age. For the
rota-rod test we initially used a maximum speed of 40 rpm, and under
these conditions KI mice actually performed signiﬁcantly better than
wild type mice (Fig. 4A). When the rota-rod test was repeated with a
maximum speed of 50 rpm, a signiﬁcant diﬀerence was no longer seen
between the two genotypes (Fig. 4B). There was also no signiﬁcant
diﬀerence between wild type and KI mice in the open ﬁeld test in terms
of time spent in the diﬀerent zones (Fig. 4C) and the distance covered
(Fig. 4D). After establishing the baseline conditions, mice were uni-
laterally injected into the striatum with α-synuclein PFFs or PBS as a
control. PFFs were generated from recombinant monomeric α-synuclein
resulting in an ~50-fold increase in thioﬂavin T ﬂuorescence (Supple-
mentary Fig. 6A). Electron microscopy analysis of ﬁbril morphology
indicated sonicated ﬁbrils ranged in size from ~20–300 nm
(Supplementary Fig. 6B). Injection into the dorsolateral striatum was
also conﬁrmed using 1% methylene blue (Supplementary Fig. 7). Fol-
lowing injection of PBS or PFFs, body weight was recorded weekly. At
12-weeks post injection, when mice were 6months of age, all mice
underwent behavioural testing again. At this time point there was no
diﬀerence in rota-rod or open ﬁeld testing and no diﬀerence in body
weight between the treatment groups or genotypes. By 18weeks post
injection however, PFF injected mice had gained signiﬁcantly more
body weight than PBS injected mice (Supplementary Fig. 8). This was
the same for both wild type and KI mice. Behavioural tests were again
performed at 24 weeks post injection, when the mice were 9months
old. There were no signiﬁcant diﬀerences between treatment groups or
genotypes for the 40 rpm rota-rod test (Fig. 4E). However, for the
50 rpm rota-rod test, KI mice performed signiﬁcantly better than wild
Fig. 3. Abnormal dopamine terminals with reduced astrocytes in the striatum of aged LRRK2 S910A/S935A KI mice. The intensity of TH (red) (A), DAT (green) (B),
Vmat2 (red) (C) and α-synuclein (green) (D) was measured in the dorsolateral striatum of wild type (n=8) and KI (n= 8) mice at 18months of age. The number of
Gfap (green) (E) positive astrocytes was also counted in the dorsolateral striatum. The number of TH (red) positive neurons (F) and the proportion of TH (red)
positive neurons co-localizing α-synuclein (green) (G) were measured in the substantia nigra from the same animals. The number of Iba1 (red) positive microglia (H)
in 40× captured view was measured in the substantia nigra pars reticulata and pars compacta. The intensity levels of the markers and the number of glia cells and TH
positive neurons in the substantia nigra were expressed as the per cent of the WT group, which was set at 100%. The blue staining is DAPI. Data are presented as
mean ± SEM. All images are representative of at least n= 20 per genotype. Student's t-test was used to compare the groups. *** indicates p < .001, and ****
indicates p < .0001 compared to the wild type mice. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of
this article.)
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type mice, regardless of whether they received PFF or PBS injections
(Fig. 4F). In the open ﬁeld test, there was a signiﬁcant diﬀerence be-
tween the PBS and PFF treatment groups, with PFF injected mice
spending more time (Fig. 4G) and covering more distance (Fig. 4H)
around the periphery of the open ﬁeld. This is indicative of an anxiety
phenotype in the PFF injected mice, and both wildtype and KI PFF in-
jected mice demonstrated this phenotype to the same extent.
3.5. Phosphorylated α-synuclein propagation following pre-formed ﬁbril
inoculation
To conﬁrm that our exogenous human α-synuclein PFFs could in-
duce pathology of endogenously expressed mouse α-synuclein, im-
munoﬂuorescent analysis of Ser129 phosphorylated α-synuclein was
performed. Fibrillar phosphorylated α-synuclein Lewy neurite-like ac-
cumulations were observed in both the ipsilateral (Supplementary
Fig. 9A) and contralateral striatum in both the PFF treated wild type
and KI mice (Fig. 5A). To determine if α-synuclein pathology had
propagated from the striatum we also assessed Ser129 phosphorylated
α-synuclein in the amygdala and SN. In the amygdala, the same ﬁbrillar
phosphorylated α-synuclein accumulations were present in the ipsi-
lateral side of both the wild type and KI PFF treated groups (Fig. 5B).
However, in the contralateral amygdala, ﬁbrillar accumulations were
only observed in the PFF injected KI mice, and not in the wild type mice
(Fig. 5B). Again, in the ipsilateral SN, α-synuclein accumulations were
observed in the PFF injected KI mouse only (Fig. 5C). In both the
amygdala (Supplementary Fig. 9B) and SN (Supplementary Fig. 9C),
these accumulations were always near DAPI-positive nuclei. Lewy
neurite and Lewy body-like pathologies were absent in ipsilateral
striatum (Fig. 5D), amygdala (Fig. 5E) and SN (Fig. 5F) of the PBS in-
jected wild type and KI mice. These results show that the PFF in-
oculations induced α-synuclein pathology and suggest that the propa-
gation of α-synuclein pathology is potentiated in the KI mice.
3.6. Quantiﬁcation of total α-synuclein following pre-formed ﬁbril
inoculation
We next measured the intensity of total α-synuclein staining in the
ipsilateral striatum (Fig. 6A), amygdala (Fig. 6B), and in SNpc TH po-
sitive neurons (Fig. 6C) for both the PFF and PBS inoculated wild type
and KI mice. In all three brain regions investigated, the α-synuclein
intensity was higher in the KI mice injected with PBS, compared to the
wild type mice injected with PBS (Fig. 6A–C). Again, in all three brain
regions, the α-synuclein intensity was higher in the PFF injected mice
compared to the PBS group (Fig. 6A–C). In comparing the PFF in-
oculated groups, the α-synuclein intensity was signiﬁcantly elevated in
the cortical nucleus of the amygdala of the PFF injected KI mice com-
pared to the PFF injected wild type mice, but there was no diﬀerence
between the two groups in α-synuclein intensity in the striatum or SN
(Fig. 6A–C). In agreement with our phosphorylated α-synuclein results,
inclusions were again observed in the striatum (Supplementary Fig. 9D)
and SN (Supplementary Fig. 9E) of the PFF injected KI mice, but not
wild type mice.
3.7. Nigrostriatal pathology with reduced astrocytes in PFF inoculated
S910A/S935 KI mice striatum
Having conﬁrmed successful induction of α-synuclein pathology
with the PFFs, we then examined their eﬀect on the nigrostriatal do-
pamine pathway in the wild type and KI mice. In the striatum of the PFF
injected KI mice, the intensities of TH immunoreactivity (Fig. 7A), and
in particular DAT immunoreactivity (Fig. 7B), were both signiﬁcantly
decreased compared to wild type PFF injected mice (10% and 28%
respectively, both p < .01). Vmat2 levels however, were unchanged
between the two genotypes (Fig. 7C). Again, there was a signiﬁcant
reduction in the number of Gfap positive astrocytes in the striatum of
the KI mice (60%, p < .001, Fig. 7D), whereas the number of Iba1
positive microglia were unchanged (Supplementary Fig. 10A). In PFF
Fig. 4. Motor phenotypes in the wild type and KI
mice before and after PBS or PFF inoculation.
Prior to stereotactic surgery, the mean latency to fall
for a maximum speed of 40 rpm (A) and 50 rpm (B)
was determined in the rotarod test for both the wild
type (n=43) and KI (n= 39) mice at 3months of
age. Time spent (C) and the total distance travelled
in the Zone 0 (edge square) to Zone 1 (centre square)
ratio (D) in the open-ﬁeld test was also assessed.
Both the rotarod (E, F) and open ﬁeld tests (G, H)
were again performed at 24 weeks post injection
with either phosphate buﬀered saline (PBS) or α-
synuclein ﬁbrils (PFF), when the mice were 9months
of age. Data are presented as mean ± SEM. Data
were analysed using Student's t-test before surgery,
and two-way ANOVA with Tukey's multiple com-
parisons test after surgery. + indicates p < .05
compared to PBS treatment, * indicates p < .05
compared to the wild type mice.
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injected mice, there was no diﬀerence in the number of TH positive
SNpc neurons between the two genotypes (Fig. 7E) and no diﬀerence in
the intensity levels of VMAT2 in SNpc neurons (Supplementary
Fig. 10B). There was however, a signiﬁcant decrease in DAT intensity in
SNpc neurons of the KI PFF injected mice compared to wild type PFF
injected mice (7%, p < .01, Fig. 7F). In the SN as a whole, there was
also no diﬀerence in Iba1 positive microglia between the two PFF in-
jected genotypes. However, there was a signiﬁcant increase in microglia
in the KI PFF injected mice if only the substantia nigra pars reticulata
was assessed (Fig. 7G). In the cortical nucleus of the amygdala, the
number of Gfap positive astrocytes was not diﬀerent between the two
PFF injected genotypes (Supplementary Fig. 10C).
4. Discussion
In this study we have utilized KI mice in which the LRRK2 phos-
phorylation sites, S910 and S935, have been mutated to alanine and can
therefore no longer be phosphorylated. Our aim was to determine the
impact of loss of LRRK2 phosphorylation on brain pathology relevant to
PD. Generation and initial validation showing loss of S910 and S935
phosphorylation in the double knockin (KI) mice has been previously
described (Ito et al., 2016). Mouse embryonic ﬁbroblasts (MEFs) de-
rived from the KI mice show similar levels of total Lrrk2 and in vitro
kinase activity compared to wild type MEFs, although phosphorylation
of the Lrrk2 substrate Rab10 (Steger et al., 2016) was markedly reduced
in KI MEFs when assessed by phos-tag assay (Ito et al., 2016). Our
characterization of tissues from the KI mice suggest an element of tissue
speciﬁcity when it comes to eﬀects of loss of Lrrk2 phosphorylation. In
particular, we found a decrease in total Lrrk2 in kidney tissue from the
KI mice whereas in brain, spleen and lung the levels of Lrrk2 were si-
milar between genotypes. The reduced levels of Lrrk2 in kidney did not
cause the morphological kidney phenotype previously seen with the
complete loss of Lrrk2 (Tong et al., 2012; Tong et al., 2010), at least in
the adult mice studied. We also found no diﬀerence in the phosphor-
ylation of Rab10 in tissues outside of kidney, suggesting that Lrrk2
kinase activity remains largely intact in the KI mice. Why this diﬀers
from the reduced Rab10 phosphorylation seen in KI MEFs is unknown,
but could be due to diﬀerent cell types/tissues analysed and/or dif-
ferent detection methodologies. Both MEFS and kidney also have re-
latively high expression levels of LRRK2 which may also contribute to a
speciﬁc eﬀect in these cell types. In regards to the diﬀerence in detec-
tion methodology we have employed a new sensitive and speciﬁc T73
Rab10 phosphorylation antibody (Lis et al., 2018) that allows phos-
phorylation only at that particular residue to be measured. We also
attempted to assess if loss of Lrrk2 phosphorylation could alter the
enzymes subcellular localization. To do this we used a tissue subcellular
fractionation protocol, as there are no widely accepted methods to as-
sess Lrrk2 subcellular localization by microscopy (Davies et al., 2013).
In most tissues and in most fractions the levels of Lrrk2 were similar in
wild-type and KI mice, suggesting no dramatic shift in enzyme locali-
zation due to loss of phosphorylation. In brain tissue of KI mice how-
ever, there was a signiﬁcant reduction in Lrrk2 levels in the membrane
fraction. Lrrk2 has been associated with intracellular membrane bound
organelles including endosomes and lysosomes (Roosen and Cookson,
2016) and increasing Lrrk2 S910/S935 phosphorylation following ac-
tivation of toll-like receptors has been reported to increase the levels of
Lrrk2 in the membrane fraction (Schapansky et al., 2014). Our data
support a role for S910/S935 phosphorylation in the regulation of Lrrk2
localization, at least in brain, but studies under conditions known to
induce phosphorylation and translocation may better reveal the extent
to which phosphorylation is required for this likely dynamic process.
We next investigated nigrostriatal PD pathology in adult (3 months)
and aged (18months) wild type and homozygous KI mice, as well as in
both genotypes following striatal inoculation with saline or PFF α-sy-
nuclein. In the 3-month old mice we found subtle but signiﬁcantly re-
duced ﬂuorescence intensity for the dopamine regulating proteins TH,
Fig. 5. Phosphorylated α-synuclein pathology in the wild type and KI mice before and after PBS or PFF inoculation. Immunoﬂuorescent analysis of Ser129 phos-
phorylated α-synuclein (green) was performed in both the ipsilateral and contralateral sites of the dorsolateral striatum (A), cortical nucleus of the amygdala (B) and
substantia nigra pars compacta (C) in the α-synuclein ﬁbrils (PFF) treated wild type and KI groups at 24weeks post inoculation. Ser129 phosphorylated α-synuclein
was also assessed in the ipsilateral sites of the dorsolateral striatum (D), cortical nucleus of the amygdala (E) and substantia nigra pars compacta (F) in the phosphate
buﬀered saline (PBS) treated group at 24weeks post inoculation. In the substantia nigra (C,F) the red staining is TH. The blue staining is DAPI. All images are
representative of at least n= 3 per mouse and at least n=4 mice were studied per group. (For interpretation of the references to colour in this ﬁgure legend, the
reader is referred to the web version of this article.)
Y. Zhao et al. Neurobiology of Disease 120 (2018) 76–87
84
DAT and Vmat2 in the striatum. In the SNpc at this timepoint, Vmat2
intensity was reduced but DAT was unchanged between genotypes. At
18months of age however, DAT intensity was now unchanged in the
striatum of the KI mice, whilst Vmat2 intensity had increased in the KI
mice. At this time point Vmat2 was unchanged in the SNpc. These re-
sults suggest an age-dependent compensation in dopamine regulating
proteins in order to maintain homeostasis. Consistent with compen-
sated dopamine homeostasis, KI mice showed no behavioural pheno-
types and there was no evidence of degeneration of SNpc TH neurons
under any conditions. Interestingly we also found reduced DAT in-
tensity in the KI mice in both the striatum and SNpc following α-sy-
nuclein PFF inoculation. Both R1441C and R1441G knockin mice,
which exhibit increased LRRK2 kinase activity, but with ~50% and
~80% loss of LRRK2 phosphorylation respectively have been studied
previously (Giesert et al., 2017; Liu et al., 2014; Tong et al., 2009).
Consistent with our results, these mice do not develop neurodegen-
eration or behavioural deﬁcits, although aged R1441G mice display gait
impairments which we did not assess in our model (Liu et al., 2014). All
three studies also report no change in striatal TH, Vmat2 and DAT le-
vels. However, R1441C mice have been reported to exhibit impaired
dopamine release following amphetamine stimulation (Tong et al.,
2009), and R1441G mice have been reported to have impaired dopa-
mine uptake following reserpine treatment (Liu et al., 2014). This
suggests an underlying defect in the regulation of proteins involved in
dopamine turnover, which can be exacerbated following challenge. Our
results from mice with normal brain Lrrk2 kinase activity but 100% loss
of Lrrk2 phosphorylation, suggest that loss of S910 and S935 phos-
phorylation may contribute to these phenotypes.
An intriguing aspect of our study was the propensity for the KI mice
to develop α-synuclein pathology. We found increased α-synuclein in-
tensity in the striatum of KI mice at 3months of age. Increased α-sy-
nuclein intensity was also observed in the 9month old KI mice that had
received striatal injections of saline. In the 18month old KI mice, α-
synuclein intensity was not increased, but α-synuclein punctate accu-
mulations could be observed in the striatum. The result was the same
for KI mice following α-synuclein PFF inoculation, with the addition
that α-synuclein inclusions could also be seen in the SN and amygdala.
Moreover α-synuclein pathology could be detected in the contralateral
amygdala, only in the KI mice, suggesting a greater degree of propa-
gation from the inoculation site. These ﬁndings diﬀer from the lack of
α-synuclein pathology observed in R1441C and R1441G knockin mice
(Giesert et al., 2017; Liu et al., 2014; Tong et al., 2009), although we
note that increased Ser129 phosphorylated α-synuclein, along with
altered levels of DAT and Vmat2, has been observed in aged G2019S
knockin mice (Longo et al., 2017). One potential explanation for these
results is the astrocyte deﬁcits seen in the phosphorylation deﬁcient KI
Fig. 6. Increased total α-synuclein intensity following PFF inoculation.
Immunoﬂuorescent analysis of total α-synuclein (green) was performed in the ipsilateral dorsolateral striatum (A) and the cortical nucleus of the amygdala (B) for
both the phosphate buﬀered saline (PBS) and α-synuclein ﬁbrils (PFF) treated wild type and KI mice at 24 weeks post inoculation. The intensity values were
expressed as the percent of the PBS treated wild type group, which was set at 100%. (C) The proportion of TH positive neurons (red) co-localizing α-synuclein (green)
in the ipsilateral substantia nigra pars compacta was also assessed for each group. The blue staining is DAPI. Data are presented as mean ± SEM. All images are
representative of at least n=3 per mouse, with at least 8 mice studied per group. Two-way ANOVA with Tukey's multiple comparisons test was used to compare the
groups. ++++ indicates p < .0001 compared to PBS treatment and ** indicates p < .01 and **** indicates p < .0001 compared to the wild type mice. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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mice. Increasing evidence suggests that astrocytes may play an im-
portant role in clearing pathological α-synuclein in PD (Cavaliere et al.,
2017; Lindstrom et al., 2017; Loria et al., 2017; Morales et al., 2017;
Rostami et al., 2017), and therefore a reduction in astrocytes may
promote α-synuclein accumulation and propagation. We found a sig-
niﬁcant age-dependent reduction in Gfap positive astrocyte numbers in
the striatum of the KI mice, which is also the site where α-synuclein
PFFs were inoculated. Little is known about LRRK2 function in astro-
cytes, although post mortem PD brain analysis suggests that LRRK2 is
indeed expressed in astrocytes (Dzamko et al., 2017), and over-
expressing pathogenic mutation forms of LRRK2 impairs the lysosomal
degradation capacity of primary mouse astrocytes (Henry et al., 2015).
Although PFF inoculation induced α-synuclein pathology, the extent
of the pathology was insuﬃcient to cause degeneration of substantia
nigra neurons in this particular study. Recently, the importance of the
biochemical properties of α-synuclein ﬁbrils in mediating neurotoxicity
have become better understood, with ﬁbril size, concentration and even
mouse strain being important (Abdelmotilib et al., 2017; Tarutani et al.,
2016). Electron microscopy analysis of our ﬁbrils indicated a size range
of ~20–300 nm, with a large proportion being longer in size. Strain
comparison studies suggest that this may be suﬃcient to cause neuro-
degeneration in mice on a C3H/HeJ background (Abdelmotilib et al.,
2017), the same strain originally used by Luk et al. to demonstrate ﬁ-
bril-mediated neurotoxicity (Luk et al., 2012). However, inclusion for-
mation and degeneration of substantia nigra neurons in C57BL6 mice,
the background strain of the currently studied mice, requires a pre-
dominantly< 50 nm ﬁbril preparation (Abdelmotilib et al., 2017).
Thus, our ﬁbril preparations may not have been optimal for assessing α-
synuclein mediated neurodegeneration, but even in aged mice we found
no evidence of dopaminergic neuron loss suggesting that the complete
loss of LRRK2 phosphorylation is not suﬃcient on its own to promote
neurodegeneration.
In conclusion, understanding LRRK2 pathobiology has been com-
plicated by the dynamic interaction between the enzymes dual GTPase
and kinase activities that also feedback to regulate LRRK2 phosphor-
ylation/localization and potentially even levels of LRRK2 itself. The
current Lrrk2 S910A/S935A KI mice provide an opportunity to better
understand the role of these residues in LRRK2 function, without also
perturbing the enzymatic activities. Our results suggest a role for these
phosphorylation sites in regulating proteins important for dopamine
turnover, and for regulating astrocyte numbers, at least in the striatum,
with potential implications for α-synuclein pathology. It is important to
note however, that the complete loss of Lrrk2 phosphorylation is be-
yond what is seen with pathogenic mutations and in idiopathic
Fig. 7. Changes in nigrostriatal pathology with reduced striatal astrocytes in PFF inoculated KI mice.
The intensity of TH (green) (A), DAT (green) (B) and Vmat2 (red) (C) was measured in the dorsolateral striatum of the α-synuclein ﬁbrils (PFF) treated wild type and
KI mice at 9months of age. The number of Gfap (red) (D) positive astrocytes were also counted in the dorsolateral striatum. The number of TH (green) positive (E)
neurons was counted in the substantia nigra of the wild type and KI mice. The intensity of DAT (green) (F) was measured in the substantia nigra neurons. The number
of Iba1 (red) positive microglia (G) in 40× captured view was also measured in the substantia nigra pars reticulata and pars compacta. The blue staining is DAPI. All
data are presented as mean ± SEM. The intensity levels of the markers and the number of glia cells and TH positive neurons in the substantia nigra were expressed as
the per cent of the wild type group, which was set at 100%. All images are representative of at least n= 4 per mouse, with at least 8 mice studied per group. Student's
t-test was used to compare the groups. ** indicates p < .01, *** indicates p < .001 and **** indicates p < .0001 compared to the wild type mice. (For inter-
pretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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postmortem brain, and likely beyond what can be achieved with LRRK2
kinase inhibitors. Indeed, LRRK2 inhibitors remain an exciting ther-
apeutic prospect for PD and it may be of interest to determine if any
phenotypes in the Lrrk2 S910A/S935A knockin mice can be reversed
with inhibitor treatment.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.nbd.2018.09.003.
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